Phase 2 Co-PSMA data showed higher lesion detection with 64Cu-SAR-bisPSMA vs 68Ga-PSMA-11 in biochemical recurrence after prostatectomy.
News|Videos|September 29, 2023
Understanding Efficacy, Safety, and PSA Kinetics of Apalutamide Plus ADT in Patients With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Author(s)Neal D. Shore, MD, FACS
Sponsored Content: Neal Shore, MD, FACS reviews new data on the TITAN trial of apalutamide in patients with mCSPC.
Advertisement
Sponsored Content: Neal Shore, MD, FACS reviews new data on the TITAN trial of apalutamide in patients with mCSPC.
This content is not certified for continuing education. The speaker has been compensated by Janssen Biotech, Inc.
Advertisement
Related to this article
Experts weigh genomic testing, treatment intensification, and radioligand sequencing in advanced prostate cancer care.
A dual antigen–targeted T-cell engager doublet produced durable PSA responses in late-line metastatic castration-resistant prostate cancer.
David VanderWeele, MD, PhD, reviews where lutetium Lu 177 vipivotide tetraxetan fits across metastatic prostate cancer, how to select and manage patients, and the new radionuclides, targeting molecules, and antigens under investigation.
Longer follow-up of CAPItello-281 showed capivasertib plus abiraterone extended survival in PTEN-deficient hormone-sensitive prostate cancer.
Lutetium Lu 177 vipivotide tetraxetan showed a median overall survival of 13.1 months in the French PSMA-REACH mCRPC cohort.
The FDA approved talazoparib plus enzalutamide in HRR-mutated prostate cancer, ivonescimab improved survival in biliary tract cancer, and more.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Breakthrough Therapy Designation to 64Cu-SAR-bisPSMA for PSMA PET in Biochemically Recurrent Prostate Cancer
2
Detalimogene Responses Improve With Longer Follow-Up in BCG-Unresponsive NMIBC Ahead of BLA Submission
3
Combination Therapy Overcomes Treatment Resistance in Breast Cancer Models
4
Dr Wander on the Evolving First-Line and Post–T-DXd Landscape in HER2+ Metastatic Breast Cancer
5